We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Clinical Evaluation of Efficacy of Lipid-Lowing Tea on Hyperlipidemia Patients’ Lipid Profiles

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2006 by China Medical University Hospital.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00316641
First Posted: April 21, 2006
Last Update Posted: November 7, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
China Medical University Hospital
  Purpose
The purpose of this study is to determine whether the Lipid-lowing Tea is effective and safe in the treatment of Hyperlipidemia Patients

Condition Intervention Phase
Hyperlipidemia Drug: Lipid-lowing Tea Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double

Resource links provided by NLM:


Further study details as provided by China Medical University Hospital:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Patient aged 20-65 years;either sex
  • Patient diagnosed with hyperlipidemia(fasting levels of TC>=200mg/dL),or TG>=200mg/dL but <400mg/dL,or LDL-C>=130mg/dL)
  • Patient who has signed the informed consent form

Exclusion Criteria:

  • Patient with pregnancy (or child bearing potential),or in lactation
  • Patient with any lipid regulating agents within 4 weeks prior to study period
  • Patient currently taking concomitant medications, such as oral contraceptives, or any medical treatment capable of interfering with lipid metabolism(eg thiazides, β-blockers, cyclosporins, itraconazole erythromycin,and danazol)
  • Patient with medical history of hypothyroidism, pancreatitis, cholestasis, nephrotic syndrome, gall bladder disease, primary biliary cirrhosis.
  • Patient with liver dysfunction (SGOT or SGPT>2x ULN)
  • Patient with renal insufficiency (serum creatinine>1.3mg/dL)
  • Patient with myocardial infarction,cerebrovascular disease,or major operations within 6 months prior to the study period.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00316641


Contacts
Contact: Chia-I Tsai, V.S 886-4-22052121 ext 5065 josepho777@yahoo.com.tw

Locations
Taiwan
China Medical University Hospital Recruiting
Taichung, Taiwan, 404
Contact: Chia-I Tsai, MD    886-4-22052121 ext 5065    josepho777@yahoo.com.tw   
Principal Investigator: Chia-I Tsai, MD         
Sponsors and Collaborators
China Medical University Hospital
Investigators
Principal Investigator: Chia-I Tsai, V.S China Medical University Hospital,Taichung,Taiwan
  More Information

ClinicalTrials.gov Identifier: NCT00316641     History of Changes
Other Study ID Numbers: DMR93-IRB-71
First Submitted: April 20, 2006
First Posted: April 21, 2006
Last Update Posted: November 7, 2006
Last Verified: March 2006

Additional relevant MeSH terms:
Hyperlipidemias
Hyperlipoproteinemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases